COVID-19 policy recommendations for OUD, pain, harm reduction
The AMA provides policy recommendations to help guide policymakers reduce the stress of patients with an opioid use disorder and pain during the COVID-19 outbreak.
New York effort raises use of MAT for opioid-use disorder
Medications for addiction treatment (MAT) are underused, with racial, geographic and economic barriers. Learn about a Big Apple initiative that’s making big changes.
After his son’s death, Massachusetts physician seeks to help others
James Baker, MD, whose son died of an overdose at 23, provides phone support to primary care doctors treating patients with substance-use disorders.
Removing prior authorization for MAT results in more patient care
Learn how Maryland has changed the law to help patients with opioid-use disorder get the evidence-based care they need.
Patient Support & Advocacy
Health care 2020: Here’s where Congress and the states are headed
The AMA’s senior VP of advocacy offers expert insight on what physicians should expect, and advises doctors looking to make a mark with policymakers.
Saving time and lives by increased access to MAT in Pennsylvania
John Gallagher, MD, asked policymakers the hard questions about why barriers to effective treatment were allowed to persist.
Changes overdue on how substance-use disorders are covered, treated
The AMA is “laser-focused” on removing barriers to treatment for opioid-use disorder—including eliminating stigma, says the organization’s president, Patrice A. Harris, MD, MA.
Membership Moves Medicine™
- Free access to JAMA Network™ and CME
- Save hundreds on insurance
- Fight for physicians and patient rights